Goodfellow Gems are chosen by Goodfellow Director, Bruce Arroll to be either practice changing or thought provoking. You are being mailed these as you are a member of the Goodfellow learning community.

Antidepressants may be effective for IBS

A recent Tools for Practice¹ reports that both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall irritable bowel syndrome (IBS) symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo.

Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA studies reported more side effects (drowsiness and dry mouth) than SSRIs. TCAs may work better for IBS-diarrhoea subtype, while SSRIs may work better for IBS-constipation subtype, but this has not been formally studied. Patients suspected of having IBS should have celiac disease ruled out.

Doses are generally on the low side e.g., TCAs starting at 10 mg and SSRI starting at 12.5 mg daily. Psychological therapies may also be effective, but the evidence is less consistent.

Reference:


 But I am not Depressed: Antidepressants for Irritable Bowel Syndrome. Tools for Practice #251 (2020) <u>View here</u>

Click here to view more Gems



Join your peers for Primary Health Care's premium CPD event.

2020 Goodfellow Symposium and pre-Symposium workshops.



If this email was forwarded to you and you would like to automatically receive Goodfellow Gems <u>Click here</u>.

Copyright © 2020 Goodfellow Unit, All rights reserved.

Our mailing address is: Goodfellow Unit University of Auckland, Grafton Campus, Bldg 507 22-30 Park Ave, Grafton, Auckland, Auckland 1023 New Zealand